Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04390906 · ClinicalTrials.gov registry record
A Study of Cognitive Changes in Patients Receiving Brain Radiation
A clinical trial of Brain Tumor Adult, sponsored by University of Rochester.
- Active
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT04390906 is a study of Brain Tumor Adult that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 75 participants, above the 67-participant average among 6 other Brain Tumor Adult trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04390906, a study of Brain Tumor Adult, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. The study will prospectively enroll 75 patients with benign and low-grade brain tumors who will undergo partial brain RT, with either conventionally fractionated or hypofractionated schedules. Subjects will receive MRI scans at baseline, 6 months, and 12 months. Given the role of the limbic system in key cognitive functions affected by RT, researchers have a particular interest in characterizing MRI changes in the limbic system and thalamus in relation to memory and related processes. Specific Aims: 1. To examine objective neurocognitive changes over time. The investigators hypothesize that they will see RT-induced neurocognitive impairment in up to 50% of patients after cranial RT. 2. To examine changes in brain tissue (via MRI) induced by off-target RT in patients with benign and low-grade brain tumors. The investigators specifically hypothesize that comapping of RT dose and MRI changes in the thalamus and limbic system (i.e., thalamic nuclei, hippocampus, fornix, hypothalamus/mammillary bodies, limbic lobe, cingulum) will be most distorted by off-target RT. 3. To examine the relationship between MRI changes for key neuroanatomic structures identified in Aim 1 with objective neurocognitive testing. The investigators hypothesize that cognitive decline will be correlated with damage revealed by MRI to limbic and thalamic structures. This research will help to define which neuroanatomic structures are most at risk from RT-induced damage and will help ultimately establish new dose constraint guidelines for important structures to improve cognitive outcomes.
Conditions Studied
Study Locations (1)
New York
- James P. Wilmot Cancer Center at University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2027-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04390906
The ClinicalTrials.gov registry entry for NCT04390906 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 6 other Brain Tumor Adult trials with a reported enrollment target (12% higher). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Tumor Adult appearing as the primary indexed condition, and to 0 interventions.
NCT04390906 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04390906 about?
NCT04390906 is a clinical study titled "A Study of Cognitive Changes in Patients Receiving Brain Radiation". Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. The study will prospectively enroll 75 patients with benign and low-grade brain tumors who wi...
What is the current status of trial NCT04390906?
This trial is currently active not recruiting. The enrollment target is 75 participants. The study started on 2018-10-16. Estimated completion is 2027-01-01.
What conditions does trial NCT04390906 study?
This clinical trial studies the following conditions: Brain Tumor Adult.
Who is sponsoring clinical trial NCT04390906?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04390906 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
-
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
RECRUITING
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures
RECRUITING · Phase 4
-
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.